The Peptide Hub
What the FDA actually reviewed each peptide for, what it is actually sold for, the real human evidence, and today's legal status. Not seller marketing.
These are FDA-approved prescription drugs, each for one specific, narrow indication. Off-label use, which is common, is a separate claim from what was actually approved and reviewed.
Reviewed for: Type 2 diabetes (Ozempic) and chronic weight management (Wegovy), each a separately approved indication.
Sold for: cosmetic microdosing and general metabolic use, off-label and beyond its approved indication.
Reviewed for: Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), each a separately approved indication.
Sold for: cosmetic microdosing and general metabolic use, off-label and beyond its approved indication.
Reviewed for: Hypoactive sexual desire disorder (HSDD) in premenopausal women (Vyleesi).
Sold for: general libido enhancement, including in men, off-label and outside the approved population.
Reviewed for: Reduction of excess abdominal fat in adults with HIV-associated lipodystrophy (Egrifta).
Sold for: off-label "GH secretagogue for longevity" use: general fat loss, muscle gain, and anti-aging.
On 23 to 24 Jul 2026, an FDA advisory committee (the Pharmacy Compounding Advisory Committee) voted to recommend these for pharmacy compounding. That vote is advisory and non-binding. Nothing became legal: formal rulemaking has not started, and analysts estimate 8 to 24 months before it could.
Reviewed for: Ulcerative colitis (PCAC review, 23 Jul 2026).
Sold for: tendon and ligament injury recovery (the "Wolverine stack").
Reviewed for: Wound healing (PCAC review, 23 Jul 2026).
Sold for: injury and tendon recovery, frequently stacked with BPC-157.
Reviewed for: Wound healing and inflammatory conditions (PCAC review, 23 Jul 2026).
Sold for: gut inflammation ("gut healing") and topical skin anti-inflammatory use.
Reviewed for: Cerebral ischemia, migraine, and trigeminal neuralgia (PCAC review, 24 Jul 2026).
Sold for: general cognitive enhancement and focus in healthy adults.
Reviewed for: Obesity and osteoporosis (PCAC review, 23 Jul 2026).
Sold for: mitochondrial function, metabolic health, and anti-aging ("exercise mimetic").
No legal path to human use exists today for these. They are sold only as unregulated research chemicals, not for human consumption.
Epitalon is not yet published on YourProtocol: the primary-source citations for its human trial claims could not be independently verified in this research pass, and we do not publish unverified claims. It will ship once that sourcing is confirmed.
See also the full peptide comparison guide for a side-by-side evidence-tier view across the wider catalogue, including peptides not yet part of this hub.